Episodes

  • Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast Cancer

    Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast Cancer
    Dec 23 2024
    Dr Aditya Bardia, Professor Giuseppe Curigliano, Dr Hope Rugo and Dr Antonio C Wolff share their perspectives on the management of HER2-low breast cancer and the potential role of emerging data from SABCS 2024.
    Show More Show Less
    1 hr and 31 mins
  • 5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 2

    5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 2
    Dec 16 2024
    Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.
    Show More Show Less
    12 mins
  • Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer 

    Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer 
    Dec 5 2024
    Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.
    Show More Show Less
    1 hr
  • 5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

    5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
    Nov 26 2024
    Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer.
    Show More Show Less
    11 mins
  • Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities

    Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities
    Nov 19 2024
    Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.
    Show More Show Less
    57 mins
  • Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Breast Cancer

    Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Breast Cancer
    Nov 16 2024
    Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.
    Show More Show Less
    1 hr and 4 mins
  • Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

    Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
    Nov 1 2024
    Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.
    Show More Show Less
    59 mins
  • Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer

    Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
    Oct 25 2024
    Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.
    Show More Show Less
    46 mins